Blackpeak is pleased to announce that it acted as Financial Advisor to Lumos Diagnostics (Lumos) on its IPO on the ASX. Lumos is a fully integrated developer and manufacturer of rapid, point-of-care (POC) diagnostic solutions. Lumos develops and manufactures proprietary and in-licensed POC diagnostic tests for commercial sale through distributors under its Products division, and develops and manufactures POC diagnostic tests on behalf of clients under its Commercial Services division. Lumos’ flagship proprietary product is FebriDx®, a point-of-care diagnostic test able to rapidly identify microbial infections in patients with acute respiratory infection symptoms and, if positive, determine if that infection is caused by a virus or bacteria.